Smoking cessation

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers

Retrieved on: 
Thursday, December 15, 2022
Research, Health, CHAI, Cervical cancer, Survival rate, NCCN, ACC, Policy, Breast, United, Childhood cancer, FACP, DAR, Smoking cessation, American Cancer Society, St. Jude Children's Research Hospital, National Comprehensive Cancer Network, Hospital, Burkitt lymphoma, Journal of the National Comprehensive Cancer Network, Learning, Prostate, ACS, Education, Virtual, Parirenyatwa Hospital, GICC, Chair, Patient, Cancer pain, Incidence, Acute lymphoblastic leukemia, Strathcona County, Global Initiative, Organization, Medical device, Dietary supplement, Medicine, Gum arabic, MD, Developing country, Cancer

DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa. These harmonized guidelines build on the successful implementation of evidence-based, expert consensus context-appropriate recommendations for managing nearly all adult cancers across more than a dozen countries throughout the region. The groups recently reunited in Dar es Salaam, Tanzania to launch four additional NCCN Harmonized Guidelines™ specifically focused on best practices for treating children with cancer.

Key Points: 
  • The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.
  • NCCN Harmonized Guidelines use color-coded recommendations for optimal cancer care in high-resource settings alongside pragmatic modifications for effective treatment options in low- and mid-resource settings.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Focuses on Resources for Children's Cancers

Retrieved on: 
Thursday, December 15, 2022
Research, Health, CHAI, Cervical cancer, Survival rate, NCCN, ACC, Policy, Breast, United, Childhood cancer, FACP, DAR, Smoking cessation, American Cancer Society, St. Jude Children's Research Hospital, National Comprehensive Cancer Network, Hospital, Burkitt lymphoma, Journal of the National Comprehensive Cancer Network, Learning, Prostate, ACS, Education, Virtual, Parirenyatwa Hospital, GICC, Chair, Patient, Cancer pain, Incidence, Acute lymphoblastic leukemia, Strathcona County, Global Initiative, Organization, Medical device, Dietary supplement, Medicine, Gum arabic, MD, Developing country, Cancer

DAR ES SALAAM, Tanzania and PLYMOUTH MEETING, Pa., Dec. 15, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is working on new NCCN Harmonized Guidelines™ for Sub-Saharan Africa, in collaboration with the African Cancer Coalition (ACC), the American Cancer Society (ACS), and the Clinton Health Access Initiative (CHAI). The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa. These harmonized guidelines build on the successful implementation of evidence-based, expert consensus context-appropriate recommendations for managing nearly all adult cancers across more than a dozen countries throughout the region. The groups recently reunited in Dar es Salaam, Tanzania to launch four additional NCCN Harmonized Guidelines™ specifically focused on best practices for treating children with cancer.

Key Points: 
  • The organizations are part of Allied Against Cancer, a global multi-sector effort to improve resource-stratified access to life-saving cancer care in Sub-Saharan Africa.
  • NCCN Harmonized Guidelines use color-coded recommendations for optimal cancer care in high-resource settings alongside pragmatic modifications for effective treatment options in low- and mid-resource settings.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.
  • NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

Digital Therapeutics (DTx) Market Report 2022: Increasing Demand for Digital Delivery of Behavioral Therapy Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 23, 2022
Health, Health Technology, MSD, Investment, Prevalence, Patient, Central nervous system disease, CRD, Digital, Medicine, Degenerative disease, Chronic Respiratory Disease, Government, Single-frequency network, Substance Abuse, Diabetes, GI, CNS, USD, CVD, Digital therapeutics, Therapy, Growth, Conditional sentence, Direct-to-consumer, Smoking cessation, Providers, Health, Sales, Pharmaceutical industry, Pharma, Rehabilitation

The adoption of digital therapeutics is growing at a fast pace owing to factors such as the rise in the number of patients with chronic diseases and growing investments in digital therapeutics.

Key Points: 
  • The adoption of digital therapeutics is growing at a fast pace owing to factors such as the rise in the number of patients with chronic diseases and growing investments in digital therapeutics.
  • On the basis of application, the digital therapeutics market is divided into preventive and treatment/care-related applications.
  • On the basis of sales channels, the digital therapeutics market is divided into business-to-customer (B2C) and business-to-business (B2B).
  • Factors such as the improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6%

Retrieved on: 
Monday, November 7, 2022
Awareness, Smoking cessation, Therapy, Growth, Investment, Degenerative disease, CAGR, Industry, Government, Chronic Respiratory Disease, Pulse, Rehabilitation, Orexo, Health, Adoption, CNS, Central nervous system disease, Medicine, Direct-to-consumer, USD, Prevalence, Conditional sentence, Diabetes, Patient, Yolo Akili, Pharmaceutical industry, Medical device, Marketing, Ginger

View original content:https://www.prnewswire.com/news-releases/the-global-digital-therapeutics...

Key Points: 
  • NEW YORK, Nov. 7, 2022 /PRNewswire/ -- The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period.
  • The adoption of digital therapeutics is growing at a fast pace owing to factors such as rise in number of patients with chronic diseases and growing investments in digital therapeutics.
  • On the basis of application, the digital therapeutics market is divided into preventive and treatment/care-related applications.
  • On the basis of sales channel, the digital therapeutics market is divided into business-to-customer (B2C) and business-to-business (B2B).

Randomized Controlled Trial Outcomes Show Pivot’s Biovalidated Smoking Cessation Quit Rates Nearly Double that of Control Program from the National Cancer Institute

Retrieved on: 
Tuesday, November 1, 2022
Oncology, Mental Health, Retail, Health, Technology, Other Technology, Tobacco, Internet access, Medical Affairs Bureau, CEO, JMIR, Smoking cessation, NPS, Tobacco, National Cancer Control Programme, National Cancer Institute, MHealth, RCT, Randomized controlled trial, FDA, Smoking, QG, Death, NRT, National, Birth control, Health insurance, Medicine, Pivot

Pivot , a behavioral change digital health company, today announced the publication of outcomes from its first randomized controlled trial (RCT) of its digital solution for tobacco cessation.

Key Points: 
  • Pivot , a behavioral change digital health company, today announced the publication of outcomes from its first randomized controlled trial (RCT) of its digital solution for tobacco cessation.
  • The study compared Pivot to a United States clinical practice guideline-based smoking cessation smartphone app from the National Cancer Institute (QuitGuide or QG).
  • Pivot participants had significantly higher engagement, net promoter score (NPS), and biovalidated cessation rates at 12 and 26 weeks compared to participants in QG.
  • The study, published in JMIR mHealth and uHealth, evaluated health outcomes in 188 adults six months after enrollment in either the Pivot program or the National Cancer Institutes QuitGuide.

Global Smoking Cessation Clinical Trial Pipeline Landscape Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 26, 2022
Health, Retail, Tobacco, Pharmaceutical, Clinical Trials, Smoking cessation, Smoking, Pharmaceutical industry, Oil

The "Global Smoking Cessation Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Smoking Cessation Clinical Trial Pipeline Highlights - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides the most up-to-date information on key pipeline products within the global Smoking Cessation market.
  • It covers emerging therapies for Smoking Cessation in active clinical development stages including early and late stage clinical trials.
  • The report provides Smoking Cessation pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Smoking Cessation & Nicotine De-Addiction Product Global Market Report 2022: Increasing Approvals and Development of New Nicotine Replacement Products Creates Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Tobacco, Retail, Pharmaceutical, Health, Online, Nicotine replacement therapy, Research report, Nicotine, Hospital, Electronic cigarette, Business Growth Fund, Use, Global, Customer support, Decision-making, Market share analysis, Value, Smoking cessation, Growth, Strategic management, Drug, CAGR, Pharmacotherapy, Drug therapy problems, Pharmacy Council of India, Nicotine gum, Tablet, Bupropion, Acquisition, Pharmacy, USD, Tobacco, Retail, Varenicline, Varenicline

This research report categorizes the Smoking Cessation & Nicotine De-Addiction Product to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Smoking Cessation & Nicotine De-Addiction Product to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product, the market was studied across Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, and Nicotine Sublingual Tablets.
  • The Nicotine Replacement Therapies is further studied across Nicotine Gums, Nicotine Lozenges, Nicotine Sprays, and Nicotine Transdermal Patches.
  • Based on Distribution, the market was studied across Drug Store, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Dr. Rod J. Rohrich Recognized as Best Facelift Surgeon in the United States by Newsweek

Retrieved on: 
Thursday, October 6, 2022
University of Texas Southwestern Medical Center, Skin care, Clinical professor, Tretinoin, Science, Anatomy, Rhinoplasty, Breast augmentation, University of Oxford, Education, Society, Patient, Distinguished Service Award, Research, Baylor University, American Society of Plastic Surgeons, Plastic, Master, University, Department, Face, ASPS, Baylor College of Medicine, Plastic surgery, PRS, Surgeon, Smoking cessation, PSF, Dentistry, DALLAS, Newsweek

DALLAS, Oct. 6, 2022 /PRNewswire-PRWeb/ -- Dallas plastic surgeon, Dr. Rod J. Rohrich, has been ranked as the top facelift surgeon in the United States in Newsweek's new peer reviewed list of top performing plastic surgeons for the second consecutive year.

Key Points: 
  • Dallas plastic surgeon, Dr. Rod J. Rohrich, has recently been recognized by Newsweek as the best facelift surgeon in the United States for the second consecutive year in their ranked list of top performing plastic surgeons.
  • DALLAS, Oct. 6, 2022 /PRNewswire-PRWeb/ -- Dallas plastic surgeon, Dr. Rod J. Rohrich , has been ranked as the top facelift surgeon in the United States in Newsweek's new peer reviewed list of top performing plastic surgeons for the second consecutive year.
  • Dr. Rohrich was ranked at number 1 for best facelift surgeon in the United States , with the top score of 93.21% based on their unique scoring system.
  • "I'm extremely honored to have my work in facelift surgery recognized by Newsweek in this extensive peer reviewed process," says Dr. Rohrich.

Axsome Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022
FDA, Migraine, Jazz Pharmaceuticals, MDD, ADHD, NDA, CNS, GLOBE, R, SYMPHONY, Food, Depression, Clinical trial, Breakthrough therapy, Smoking, Narcolepsy, Lists of diseases, Fibromyalgia, Research, Endpoint security, Patient, Agitation, Therapy, Company, Review, Mission statement, Central nervous system disease, SG, Acquisition, Central nervous system, ASCEND, Safety, NASDAQ, Priority review, Reboxetine, Webcast, Food and Drug Administration, Physician, ACCORD, MD, NMDA, Smoking cessation, GEMINI, Medical device, Pharmaceutical industry, Video game, COVID-19, Solriamfetol

NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2022.

Key Points: 
  • NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2022.
  • We are very pleased to report our first commercial sales following the closing of the Sunosi acquisition in the second quarter.
  • Axsome generated approximately $8.8 million in U.S. net sales of Sunosi from May 9 to June 30, 2022.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss second quarter 2022 financial results as well as to provide a corporate update.

Velocity Clinical Research begins European expansion with German site acquisition

Retrieved on: 
Wednesday, July 27, 2022
Running, Acquisition, Osteology, Urology, III, IV, Data collection, Dermatology, Research, Cros, Gastroenterology, Health, Pain management, Patient, Hypertension, Neurology, Internal medicine, Endocrinology, Smoking cessation, II, Vaccine, Pharmaceutical industry, Medical device, EU, Velocity

DURHAM, N.C., July 27, 2022 /PRNewswire/ -- Velocity Clinical Research ("Velocity"), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount.

Key Points: 
  • DURHAM, N.C., July 27, 2022 /PRNewswire/ -- Velocity Clinical Research ("Velocity"), the leading integrated research site organisation, today announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount.
  • "Velocity Clinical Research is breaking new ground for the clinical research industry.
  • As a result, Clinical Research Organizations and big pharmaceutical companies can benefit from simplified access to international clinical research.
  • Dr. Christine Grigat, Managing Director, Clinical Research Hamburg, commented, "Clinical Research Hamburg is known for being a high quality and successful dedicated research site.